Assessment of urinary pharmacodynamic profiles of faropenem against extended-spectrum β-lactamase-producing Escherichia coli with canine ex vivo modeling
K. Harada, T. Shimizu, N. Miyashita, Y. Hikasa
This study evaluates faropenem's urinary pharmacodynamics against ESBL-producing E. coli in dogs using an ex vivo model, finding that higher AUBT values correlate with lower MICs and supporting more frequent dosing.
bioRxiv · May 14, 2018Microbiology